dsp107
Recombinant proteinexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 7, 2020 (NCT04440735)
Timeline
Indications
Mechanism of action
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07235293 | Phase 2 | Nov 15, 2025 | Kahr Medical, Novotech |
| NCT04937166 | Phase 1 | Oct 31, 2021 | Kahr Medical |
| NCT04440735 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2020 | Kahr Medical, University of California, San Diego, University of Pittsburgh |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kahr Medical | For profit | 3 | 3 | 2 | 2020 |
| Novotech | For profit | 1 | 0 | 1 | 2025 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1